Guardant Health

Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.  

The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.

Medicare Administrative Contractor Palmetto released its final local coverage decision last year, and WPSIC has now aligned its coverage.

The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.

A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.

Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.